**Core Concept**
Selegiline is a selective, irreversible inhibitor of monoamine oxidase B (MAO-B) enzyme, primarily used in the treatment of Parkinson's disease. MAO-B is responsible for the breakdown of dopamine in the brain, and its inhibition leads to increased levels of dopamine, thereby alleviating symptoms of Parkinson's disease.

**Why the Correct Answer is Right**
The correct answer states that selegiline is a MAO-A inhibitor, which is incorrect. Selegiline is actually a selective, irreversible inhibitor of MAO-B, not MAO-A. MAO-A is involved in the breakdown of serotonin and norepinephrine, whereas MAO-B is primarily responsible for the breakdown of dopamine. The selectivity of selegiline for MAO-B is crucial, as it reduces the risk of adverse effects associated with MAO-A inhibition, such as the "cheese reaction." This reaction occurs when MAO-A is inhibited, allowing tyramine (found in aged cheese) to accumulate and cause a dangerous increase in blood pressure.

**Why Each Wrong Option is Incorrect**
**Option A:** Selegiline is not a MAO-A inhibitor; it is a selective, irreversible inhibitor of MAO-B.

**Option B:** Selegiline does not entirely eliminate the risk of the "cheese reaction," as it is still a monoamine oxidase inhibitor (MAOI). However, its selectivity for MAO-B reduces the risk compared to non-selective MAOIs.

**Option C:** Selegiline is indeed used in the management of the on-off phenomenon in Parkinson's disease, which is a fluctuation in motor symptoms between periods of good mobility and periods of immobility.

**Option D:** Selegiline is used in the treatment of Parkinson's disease, making this statement correct.

**Clinical Pearl / High-Yield Fact**
It is essential to remember that selegiline's selectivity for MAO-B is critical in reducing the risk of adverse effects associated with MAO-A inhibition. This highlights the importance of understanding the specific pharmacological properties of a medication in its clinical application.

**✓ Correct Answer: A. It is a MAO -A inhibitor**